The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugate (ADC) Drug Market Research Report 2024
Synopsis
The global Antibody Drug Conjugate (ADC) Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate (ADC) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate (ADC) Drug.
Report Scope
The Antibody Drug Conjugate (ADC) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate (ADC) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate (ADC) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Oxford Bio Therapeutics
Synthon
Progenics Pharmaceuticals
Bayer HealthCare
Millennium Pharmaceuticals
Pfizer
Concortis Bio therapeutics
Roche Holding AG
Seattle Genetics
Heidelberg Pharma
Mersana Therapeutics
Astellas Pharma/Agensys
AbbVie Inc
Celldex Therapeutics
Immunomedics
Agensys
Genentech
ImmunoGen
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
Segment by Type
by Technology
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
by Product Type
Kadcyla
Adcertis
Segment by Application
Biotechnology Companies
Specialized Cancer Centers
Biopharmaceutical Companies
Academic Research Institutes
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate (ADC) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Antibody Drug Conjugate (ADC) Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate (ADC) Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate (ADC) Drug.
Report Scope
The Antibody Drug Conjugate (ADC) Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate (ADC) Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate (ADC) Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Oxford Bio Therapeutics
Synthon
Progenics Pharmaceuticals
Bayer HealthCare
Millennium Pharmaceuticals
Pfizer
Concortis Bio therapeutics
Roche Holding AG
Seattle Genetics
Heidelberg Pharma
Mersana Therapeutics
Astellas Pharma/Agensys
AbbVie Inc
Celldex Therapeutics
Immunomedics
Agensys
Genentech
ImmunoGen
Sanofi
Genmab
Amgen
Novartis
Eli Lilly
Segment by Type
by Technology
Mmunomedics Technology
Immunogen Technology
Seattle Genetics Technology
Others
by Product Type
Kadcyla
Adcertis
Segment by Application
Biotechnology Companies
Specialized Cancer Centers
Biopharmaceutical Companies
Academic Research Institutes
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate (ADC) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Technology
1.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Technology: 2019 VS 2023 VS 2030
1.2.2 Mmunomedics Technology
1.2.3 Immunogen Technology
1.2.4 Seattle Genetics Technology
1.2.5 Others
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate (ADC) Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology Companies
1.3.3 Specialized Cancer Centers
1.3.4 Biopharmaceutical Companies
1.3.5 Academic Research Institutes
1.3.6 Hospitals
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate (ADC) Drug Market Perspective (2019-2030)
2.2 Antibody Drug Conjugate (ADC) Drug Growth Trends by Region
2.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody Drug Conjugate (ADC) Drug Historic Market Size by Region (2019-2024)
2.2.3 Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Region (2025-2030)
2.3 Antibody Drug Conjugate (ADC) Drug Market Dynamics
2.3.1 Antibody Drug Conjugate (ADC) Drug Industry Trends
2.3.2 Antibody Drug Conjugate (ADC) Drug Market Drivers
2.3.3 Antibody Drug Conjugate (ADC) Drug Market Challenges
2.3.4 Antibody Drug Conjugate (ADC) Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate (ADC) Drug Players by Revenue (2019-2024)
3.1.2 Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Players (2019-2024)
3.2 Global Antibody Drug Conjugate (ADC) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antibody Drug Conjugate (ADC) Drug Revenue
3.4 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate (ADC) Drug Revenue in 2023
3.5 Antibody Drug Conjugate (ADC) Drug Key Players Head office and Area Served
3.6 Key Players Antibody Drug Conjugate (ADC) Drug Product Solution and Service
3.7 Date of Enter into Antibody Drug Conjugate (ADC) Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Type
4.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Type (2019-2024)
4.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Type (2025-2030)
5 Antibody Drug Conjugate (ADC) Drug Breakdown Data by Application
5.1 Global Antibody Drug Conjugate (ADC) Drug Historic Market Size by Application (2019-2024)
5.2 Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody Drug Conjugate (ADC) Drug Market Size (2019-2030)
6.2 North America Antibody Drug Conjugate (ADC) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024)
6.4 North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size (2019-2030)
7.2 Europe Antibody Drug Conjugate (ADC) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024)
7.4 Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size (2019-2030)
8.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size (2019-2030)
9.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024)
9.4 Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size (2019-2030)
10.2 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Oxford Bio Therapeutics
11.1.1 Oxford Bio Therapeutics Company Detail
11.1.2 Oxford Bio Therapeutics Business Overview
11.1.3 Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.1.4 Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.1.5 Oxford Bio Therapeutics Recent Development
11.2 Synthon
11.2.1 Synthon Company Detail
11.2.2 Synthon Business Overview
11.2.3 Synthon Antibody Drug Conjugate (ADC) Drug Introduction
11.2.4 Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.2.5 Synthon Recent Development
11.3 Progenics Pharmaceuticals
11.3.1 Progenics Pharmaceuticals Company Detail
11.3.2 Progenics Pharmaceuticals Business Overview
11.3.3 Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.3.4 Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.3.5 Progenics Pharmaceuticals Recent Development
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Company Detail
11.4.2 Bayer HealthCare Business Overview
11.4.3 Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Introduction
11.4.4 Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.4.5 Bayer HealthCare Recent Development
11.5 Millennium Pharmaceuticals
11.5.1 Millennium Pharmaceuticals Company Detail
11.5.2 Millennium Pharmaceuticals Business Overview
11.5.3 Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction
11.5.4 Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.5.5 Millennium Pharmaceuticals Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Antibody Drug Conjugate (ADC) Drug Introduction
11.6.4 Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Concortis Bio therapeutics
11.7.1 Concortis Bio therapeutics Company Detail
11.7.2 Concortis Bio therapeutics Business Overview
11.7.3 Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.7.4 Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.7.5 Concortis Bio therapeutics Recent Development
11.8 Roche Holding AG
11.8.1 Roche Holding AG Company Detail
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Antibody Drug Conjugate (ADC) Drug Introduction
11.8.4 Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.8.5 Roche Holding AG Recent Development
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Detail
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Antibody Drug Conjugate (ADC) Drug Introduction
11.9.4 Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.9.5 Seattle Genetics Recent Development
11.10 Heidelberg Pharma
11.10.1 Heidelberg Pharma Company Detail
11.10.2 Heidelberg Pharma Business Overview
11.10.3 Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Introduction
11.10.4 Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.10.5 Heidelberg Pharma Recent Development
11.11 Mersana Therapeutics
11.11.1 Mersana Therapeutics Company Detail
11.11.2 Mersana Therapeutics Business Overview
11.11.3 Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.11.4 Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.11.5 Mersana Therapeutics Recent Development
11.12 Astellas Pharma/Agensys
11.12.1 Astellas Pharma/Agensys Company Detail
11.12.2 Astellas Pharma/Agensys Business Overview
11.12.3 Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.12.4 Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.12.5 Astellas Pharma/Agensys Recent Development
11.13 AbbVie Inc
11.13.1 AbbVie Inc Company Detail
11.13.2 AbbVie Inc Business Overview
11.13.3 AbbVie Inc Antibody Drug Conjugate (ADC) Drug Introduction
11.13.4 AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.13.5 AbbVie Inc Recent Development
11.14 Celldex Therapeutics
11.14.1 Celldex Therapeutics Company Detail
11.14.2 Celldex Therapeutics Business Overview
11.14.3 Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction
11.14.4 Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.14.5 Celldex Therapeutics Recent Development
11.15 Immunomedics
11.15.1 Immunomedics Company Detail
11.15.2 Immunomedics Business Overview
11.15.3 Immunomedics Antibody Drug Conjugate (ADC) Drug Introduction
11.15.4 Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.15.5 Immunomedics Recent Development
11.16 Agensys
11.16.1 Agensys Company Detail
11.16.2 Agensys Business Overview
11.16.3 Agensys Antibody Drug Conjugate (ADC) Drug Introduction
11.16.4 Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.16.5 Agensys Recent Development
11.17 Genentech
11.17.1 Genentech Company Detail
11.17.2 Genentech Business Overview
11.17.3 Genentech Antibody Drug Conjugate (ADC) Drug Introduction
11.17.4 Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.17.5 Genentech Recent Development
11.18 ImmunoGen
11.18.1 ImmunoGen Company Detail
11.18.2 ImmunoGen Business Overview
11.18.3 ImmunoGen Antibody Drug Conjugate (ADC) Drug Introduction
11.18.4 ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.18.5 ImmunoGen Recent Development
11.19 Sanofi
11.19.1 Sanofi Company Detail
11.19.2 Sanofi Business Overview
11.19.3 Sanofi Antibody Drug Conjugate (ADC) Drug Introduction
11.19.4 Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.19.5 Sanofi Recent Development
11.20 Genmab
11.20.1 Genmab Company Detail
11.20.2 Genmab Business Overview
11.20.3 Genmab Antibody Drug Conjugate (ADC) Drug Introduction
11.20.4 Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.20.5 Genmab Recent Development
11.21 Amgen
11.21.1 Amgen Company Detail
11.21.2 Amgen Business Overview
11.21.3 Amgen Antibody Drug Conjugate (ADC) Drug Introduction
11.21.4 Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.21.5 Amgen Recent Development
11.22 Novartis
11.22.1 Novartis Company Detail
11.22.2 Novartis Business Overview
11.22.3 Novartis Antibody Drug Conjugate (ADC) Drug Introduction
11.22.4 Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.22.5 Novartis Recent Development
11.23 Eli Lilly
11.23.1 Eli Lilly Company Detail
11.23.2 Eli Lilly Business Overview
11.23.3 Eli Lilly Antibody Drug Conjugate (ADC) Drug Introduction
11.23.4 Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
11.23.5 Eli Lilly Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Mmunomedics Technology
Table 3. Key Players of Immunogen Technology
Table 4. Key Players of Seattle Genetics Technology
Table 5. Key Players of Others
Table 6. Global Antibody Drug Conjugate (ADC) Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Antibody Drug Conjugate (ADC) Drug Market Share by Region (2019-2024)
Table 10. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Antibody Drug Conjugate (ADC) Drug Market Share by Region (2025-2030)
Table 12. Antibody Drug Conjugate (ADC) Drug Market Trends
Table 13. Antibody Drug Conjugate (ADC) Drug Market Drivers
Table 14. Antibody Drug Conjugate (ADC) Drug Market Challenges
Table 15. Antibody Drug Conjugate (ADC) Drug Market Restraints
Table 16. Global Antibody Drug Conjugate (ADC) Drug Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Antibody Drug Conjugate (ADC) Drug Market Share by Players (2019-2024)
Table 18. Global Top Antibody Drug Conjugate (ADC) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate (ADC) Drug as of 2023)
Table 19. Ranking of Global Top Antibody Drug Conjugate (ADC) Drug Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Antibody Drug Conjugate (ADC) Drug Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Antibody Drug Conjugate (ADC) Drug Product Solution and Service
Table 23. Date of Enter into Antibody Drug Conjugate (ADC) Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Antibody Drug Conjugate (ADC) Drug Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2019-2024)
Table 27. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Type (2025-2030)
Table 29. Global Antibody Drug Conjugate (ADC) Drug Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Application (2019-2024)
Table 31. Global Antibody Drug Conjugate (ADC) Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Antibody Drug Conjugate (ADC) Drug Revenue Market Share by Application (2025-2030)
Table 33. North America Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size by Country (2025-2030) & (US$ Million)
Table 48. Oxford Bio Therapeutics Company Detail
Table 49. Oxford Bio Therapeutics Business Overview
Table 50. Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 51. Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 52. Oxford Bio Therapeutics Recent Development
Table 53. Synthon Company Detail
Table 54. Synthon Business Overview
Table 55. Synthon Antibody Drug Conjugate (ADC) Drug Product
Table 56. Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 57. Synthon Recent Development
Table 58. Progenics Pharmaceuticals Company Detail
Table 59. Progenics Pharmaceuticals Business Overview
Table 60. Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product
Table 61. Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 62. Progenics Pharmaceuticals Recent Development
Table 63. Bayer HealthCare Company Detail
Table 64. Bayer HealthCare Business Overview
Table 65. Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Product
Table 66. Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 67. Bayer HealthCare Recent Development
Table 68. Millennium Pharmaceuticals Company Detail
Table 69. Millennium Pharmaceuticals Business Overview
Table 70. Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product
Table 71. Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 72. Millennium Pharmaceuticals Recent Development
Table 73. Pfizer Company Detail
Table 74. Pfizer Business Overview
Table 75. Pfizer Antibody Drug Conjugate (ADC) Drug Product
Table 76. Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Concortis Bio therapeutics Company Detail
Table 79. Concortis Bio therapeutics Business Overview
Table 80. Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 81. Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 82. Concortis Bio therapeutics Recent Development
Table 83. Roche Holding AG Company Detail
Table 84. Roche Holding AG Business Overview
Table 85. Roche Holding AG Antibody Drug Conjugate (ADC) Drug Product
Table 86. Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 87. Roche Holding AG Recent Development
Table 88. Seattle Genetics Company Detail
Table 89. Seattle Genetics Business Overview
Table 90. Seattle Genetics Antibody Drug Conjugate (ADC) Drug Product
Table 91. Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 92. Seattle Genetics Recent Development
Table 93. Heidelberg Pharma Company Detail
Table 94. Heidelberg Pharma Business Overview
Table 95. Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Product
Table 96. Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 97. Heidelberg Pharma Recent Development
Table 98. Mersana Therapeutics Company Detail
Table 99. Mersana Therapeutics Business Overview
Table 100. Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 101. Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 102. Mersana Therapeutics Recent Development
Table 103. Astellas Pharma/Agensys Company Detail
Table 104. Astellas Pharma/Agensys Business Overview
Table 105. Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Product
Table 106. Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 107. Astellas Pharma/Agensys Recent Development
Table 108. AbbVie Inc Company Detail
Table 109. AbbVie Inc Business Overview
Table 110. AbbVie Inc Antibody Drug Conjugate (ADC) Drug Product
Table 111. AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 112. AbbVie Inc Recent Development
Table 113. Celldex Therapeutics Company Detail
Table 114. Celldex Therapeutics Business Overview
Table 115. Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Product
Table 116. Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 117. Celldex Therapeutics Recent Development
Table 118. Immunomedics Company Detail
Table 119. Immunomedics Business Overview
Table 120. Immunomedics Antibody Drug Conjugate (ADC) Drug Product
Table 121. Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 122. Immunomedics Recent Development
Table 123. Agensys Company Detail
Table 124. Agensys Business Overview
Table 125. Agensys Antibody Drug Conjugate (ADC) Drug Product
Table 126. Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 127. Agensys Recent Development
Table 128. Genentech Company Detail
Table 129. Genentech Business Overview
Table 130. Genentech Antibody Drug Conjugate (ADC) Drug Product
Table 131. Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 132. Genentech Recent Development
Table 133. ImmunoGen Company Detail
Table 134. ImmunoGen Business Overview
Table 135. ImmunoGen Antibody Drug Conjugate (ADC) Drug Product
Table 136. ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 137. ImmunoGen Recent Development
Table 138. Sanofi Company Detail
Table 139. Sanofi Business Overview
Table 140. Sanofi Antibody Drug Conjugate (ADC) Drug Product
Table 141. Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 142. Sanofi Recent Development
Table 143. Genmab Company Detail
Table 144. Genmab Business Overview
Table 145. Genmab Antibody Drug Conjugate (ADC) Drug Product
Table 146. Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 147. Genmab Recent Development
Table 148. Amgen Company Detail
Table 149. Amgen Business Overview
Table 150. Amgen Antibody Drug Conjugate (ADC) Drug Product
Table 151. Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 152. Amgen Recent Development
Table 153. Novartis Company Detail
Table 154. Novartis Business Overview
Table 155. Novartis Antibody Drug Conjugate (ADC) Drug Product
Table 156. Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 157. Novartis Recent Development
Table 158. Eli Lilly Company Detail
Table 159. Eli Lilly Business Overview
Table 160. Eli Lilly Antibody Drug Conjugate (ADC) Drug Product
Table 161. Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2019-2024) & (US$ Million)
Table 162. Eli Lilly Recent Development
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antibody Drug Conjugate (ADC) Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Antibody Drug Conjugate (ADC) Drug Market Share by Type: 2023 VS 2030
Figure 3. Mmunomedics Technology Features
Figure 4. Immunogen Technology Features
Figure 5. Seattle Genetics Technology Features
Figure 6. Others Features
Figure 7. Global Antibody Drug Conjugate (ADC) Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Antibody Drug Conjugate (ADC) Drug Market Share by Application: 2023 VS 2030
Figure 9. Biotechnology Companies Case Studies
Figure 10. Specialized Cancer Centers Case Studies
Figure 11. Biopharmaceutical Companies Case Studies
Figure 12. Academic Research Institutes Case Studies
Figure 13. Hospitals Case Studies
Figure 14. Others Case Studies
Figure 15. Antibody Drug Conjugate (ADC) Drug Report Years Considered
Figure 16. Global Antibody Drug Conjugate (ADC) Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 17. Global Antibody Drug Conjugate (ADC) Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 18. Global Antibody Drug Conjugate (ADC) Drug Market Share by Region: 2023 VS 2030
Figure 19. Global Antibody Drug Conjugate (ADC) Drug Market Share by Players in 2023
Figure 20. Global Top Antibody Drug Conjugate (ADC) Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate (ADC) Drug as of 2023)
Figure 21. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate (ADC) Drug Revenue in 2023
Figure 22. North America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. North America Antibody Drug Conjugate (ADC) Drug Market Share by Country (2019-2030)
Figure 24. United States Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Canada Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Europe Antibody Drug Conjugate (ADC) Drug Market Share by Country (2019-2030)
Figure 28. Germany Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. France Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. U.K. Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Italy Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Russia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Nordic Countries Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Share by Region (2019-2030)
Figure 36. China Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Japan Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. South Korea Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Southeast Asia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. India Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Australia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Latin America Antibody Drug Conjugate (ADC) Drug Market Share by Country (2019-2030)
Figure 44. Mexico Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Brazil Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Share by Country (2019-2030)
Figure 48. Turkey Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Saudi Arabia Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Oxford Bio Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 51. Synthon Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 52. Progenics Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 53. Bayer HealthCare Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 54. Millennium Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 55. Pfizer Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 56. Concortis Bio therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 57. Roche Holding AG Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 58. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 59. Heidelberg Pharma Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 60. Mersana Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 61. Astellas Pharma/Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 62. AbbVie Inc Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 63. Celldex Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 64. Immunomedics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 65. Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 66. Genentech Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 67. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 68. Sanofi Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 69. Genmab Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 70. Amgen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 71. Novartis Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 72. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2019-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
